Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Journal Title:
Blood
Original Publication Date:
May 2020
Bone Marrow Disease(s):
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
Journal Title:
Annals of Hematology
Original Publication Date:
May 2020
Bone Marrow Disease(s):
Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
SF3B1 Variant in MDS Found to Identify Distinct Disease Entities
Cancer and Coronavirus Disease 2019 (COVID-19)—Facing the “C Words”
By Urvi A. Shah, MD from JAMA Oncology
Dr. Eunice Wang discusses Secondary MDS
Dr. Eunice Wang explains the origin and treatment of secondary MDS. Dr. Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Center.
Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator
Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator. Dr. Steensma is an associate professor at Harvard Medical School and faculty member in the leukemia program at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, Massachusetts and the Edward P. Evans Chair in MDS at Dana-Farber Cancer Institute
COVID-19 outcomes in patients with hematologic disease
To the Editor:
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Key Points
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Journal Title:
Blood Advances
Original Publication Date:
Apr 2020
Bone Marrow Disease(s):